ELDN

Eledon Pharmaceuticals, Inc.

Eledon Pharmaceuticals, Inc., clinical stage biopharmaceutical company, focuses on developing medicines for the patients living with autoimmune disease and amyotrophic lateral sclerosis (ALS), and requiring an organ or cell-based transplant. Its lead product candidate includes AT-1501, a humanized monoclonal antibody to target CD40 Ligand that is a molecule expressed on the surface of human immune system T cells, which is in Phase 2a clinical trials for the treatment of ALS, and Phase 2 clinical trials in islet cell transplantation for the treatment of type 1 diabetes. The company was formerly known as Novus Therapeutics, Inc. and changed its name to Eledon Pharmaceuticals, Inc. in January 2021. Eledon Pharmaceuticals, Inc. is headquartered in Irvine, California.

Eledon Pharmaceuticals, Inc. (ELDN) is rated C (2.2/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Revisions (C+); its weakest is Momentum (C-). The rating has held at C for 13 weeks.

Quantitative Factor Evaluation • Updated

Overall Rating
2.2 / 5.0
C
Value
C+
Factor Score 2.5 / 5.0
Growth
C-
Factor Score 2.1 / 5.0
Profitability
C-
Factor Score 2.0 / 5.0
Momentum
C-
Factor Score 1.9 / 5.0
Revisions
C+
Factor Score 2.6 / 5.0

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Underlying Financial Metrics

P/E Ratio -3.6
EV / EBITDA N/A
Rev Growth YoY N/A
Gross Margin 0.0%
Price Return 3M -26.8%
Price Return 12M 34.0%
Catalyst Signal 0.00
Market Cap $224.3M
TTM Revenue N/A
Price / Sales N/A
ROE -110.7%

Historical Factor Score Progression

Held C for 13 weeks
Date Value Growth Profitability Momentum Revisions Overall
2026-11-11 C+ (2.5) C- (2.1) C- (2.0) C- (1.9) C+ (2.6) C (2.2)
2026-11-04 C+ (2.5) C- (2.1) C- (2.1) D+ (1.8) C+ (2.7) C (2.2)
2026-10-28 C+ (2.5) C- (2.1) C (2.2) D+ (1.8) C+ (2.7) C (2.2)
2026-10-21 C+ (2.5) C- (2.1) C- (2.1) D (1.5) C+ (2.6) C (2.2)
2026-10-14 C+ (2.5) C- (2.1) C- (2.1) D+ (1.8) C+ (2.6) C (2.2)
Page 1 of 3